- For Print
- March 15, 2022
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today.
Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown in the table below.
Royalty rates to be received by Eisai
|Net Sales of Aduhelm in any Calendar Year
Less than or equal to $250 million
|Greater than $250 million less than or equal to $500 million||3.5%|
Greater than $500 million and less than or equal to $1.0 billion
|Greater than $1.0 billion||8%|
Economic arrangements for 2022 will remain materially unchanged with Eisai’s share of ADUHELM expenses capped at $335 million for the costs related to development, commercialization and manufacturing for the period from January 1, 2022, to December 31, 2022.
In regards to Eisai’s financials, no revision will be made at this time to the consolidated earnings forecast for the fiscal year ending March 31, 2022. If Eisai determines that revisions are necessary based on changes including business environment, Eisai will make an announcement as soon as possible.
A link to the news release announced today regarding the amendment of collaboration agreements with Biogen on Alzheimer’s disease treatments is here.
ADUHELM® is a registered trademark of Biogen Inc.
Public Relations Department,
Eisai Co., Ltd.